

Kenneth D Westover

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8930179/publications.pdf>

Version: 2024-02-01

129
papers

8,065
citations

71102

41
h-index

51608

86
g-index

142
all docs

142
docs citations

142
times ranked

11887
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, e173501.	7.1	755
2	Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition. <i>Cell</i> , 2012, 150, 987-1001.	28.9	723
3	Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. <i>Molecular Cancer Research</i> , 2015, 13, 1325-1335.	3.4	503
4	Structural Basis of Transcription: Role of the Trigger Loop in Substrate Specificity and Catalysis. <i>Cell</i> , 2006, 127, 941-954.	28.9	421
5	A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. <i>Nature Chemical Biology</i> , 2016, 12, 452-458.	8.0	389
6	Structural Basis of Transcription: An RNA Polymerase II-TFIIB Cocrystal at 4.5 Angstroms. <i>Science</i> , 2004, 303, 983-988.	12.6	307
7	Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 199-204.	13.8	262
8	Structural Basis of Transcription. <i>Cell</i> , 2004, 119, 481-489.	28.9	248
9	Structural Basis of Transcription: Separation of RNA from DNA by RNA Polymerase II. <i>Science</i> , 2004, 303, 1014-1016.	12.6	231
10	Structural Basis of Transcription: Backtracked RNA Polymerase II at 3.4 Angstrom Resolution. <i>Science</i> , 2009, 324, 1203-1206.	12.6	225
11	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. <i>Cell</i> , 2018, 172, 857-868.e15.	28.9	220
12	In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 8895-8900.	7.1	193
13	Exploring Targeted Degradation Strategy for Oncogenic KRASG12C. <i>Cell Chemical Biology</i> , 2020, 27, 19-31.e6.	5.2	182
14	Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR. <i>Cancer Research</i> , 2013, 73, 2574-2586.	0.9	170
15	Pharmacological targeting of the pseudokinase Her3. <i>Nature Chemical Biology</i> , 2014, 10, 1006-1012.	8.0	161
16	Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 280-285.	1.1	154
17	Tissue-Specific Oncogenic Activity of KRASA146T. <i>Cancer Discovery</i> , 2019, 9, 738-755.	9.4	127
18	Structural basis of eukaryotic gene transcription. <i>FEBS Letters</i> , 2005, 579, 899-903.	2.8	120

#	ARTICLE	IF	CITATIONS
19	Data publication with the structural biology data grid supports live analysis. <i>Nature Communications</i> , 2016, 7, 10882.	12.8	113
20	Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. <i>Cell Chemical Biology</i> , 2017, 24, 1005-1016.e3.	5.2	109
21	Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF- $\hat{\pm}$ Inhibition for Cancer and Autoimmune Disease. <i>Cell Chemical Biology</i> , 2017, 24, 1029-1039.e7.	5.2	104
22	Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. <i>Cell Chemical Biology</i> , 2019, 26, 792-803.e10.	5.2	103
23	Direct Targeting of $\hat{\Gamma}^2$ -Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/ Γ^2 -Catenin Signaling. <i>Cell Reports</i> , 2016, 16, 28-36.	6.4	98
24	Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics. <i>Journal of Biological Chemistry</i> , 2012, 287, 9742-9752.	3.4	89
25	Discovery of a selective inhibitor of doublecortin like kinase 1. <i>Nature Chemical Biology</i> , 2020, 16, 635-643.	8.0	84
26	Mechanism of Rab Geranylgeranylation:Â Formation of the Catalytic Ternary Complexâ€. <i>Biochemistry</i> , 1998, 37, 12559-12568.	2.5	81
27	Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. <i>American Journal of Veterinary Research</i> , 2004, 65, 810-818.	0.6	75
28	Nonsteroidal Anti-Inflammatory Drugs, Acetaminophen, Cyclooxygenase 2, and Fever. <i>Clinical Infectious Diseases</i> , 2000, 31, S211-S218.	5.8	70
29	Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine. <i>Journal of Biological Chemistry</i> , 2017, 292, 112-120.	3.4	70
30	Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active center. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17361-17364.	7.1	66
31	Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 72-81.	0.8	62
32	Discovery of Type II Inhibitors of TGF $\hat{\Gamma}^2$ -Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase 2 (MAP4K2). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 183-196.	6.4	62
33	Proton SBRT for Medically Inoperable Stage I NSCLC. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1021-1025.	1.1	61
34	Covalent Guanosine Mimetic Inhibitors of G12C KRAS. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 61-66.	2.8	59
35	Development of small molecules targeting the pseudokinase Her3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3382-3389.	2.2	53
36	Treatment of Non-Small Cell Lung Cancer Patients With Proton Beam-Based Stereotactic Body Radiotherapy: Dosimetric Comparison With Photon Plans Highlights Importance of Range Uncertainty. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 354-361.	0.8	52

#	ARTICLE	IF	CITATIONS
37	Radical prostatectomy vs radiation therapy and androgen suppression therapy in high-risk prostate cancer. <i>BJU International</i> , 2012, 110, 1116-1121.	2.5	46
38	Genome-wide distribution of histone H4 Lysine 16 acetylation sites and their relationship to gene expression. <i>Genome Integrity</i> , 2013, 4, 3.	1.0	46
39	Multi-objective radiomics model for predicting distant failure in lung SBRT. <i>Physics in Medicine and Biology</i> , 2017, 62, 4460-4478.	3.0	46
40	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status. <i>JAMA Oncology</i> , 2021, 7, 1497.	7.1	45
41	A structural model of a Ras-Raf signalosome. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 847-857.	8.2	44
42	Accurate real time localization tracking in a clinical environment using Bluetooth Low Energy and deep learning. <i>PLoS ONE</i> , 2018, 13, e0205392.	2.5	43
43	Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. <i>Cell Chemical Biology</i> , 2019, 26, 818-829.e9.	5.2	43
44	Shell feature: a new radiomics descriptor for predicting distant failure after radiotherapy in non-small cell lung cancer and cervix cancer. <i>Physics in Medicine and Biology</i> , 2018, 63, 095007.	3.0	42
45	KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation. <i>Biochemistry</i> , 2018, 57, 324-333.	2.5	40
46	Predicting distant failure in early stage NSCLC treated with SBRT using clinical parameters. <i>Radiotherapy and Oncology</i> , 2016, 119, 501-504.	0.6	39
47	Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 220.	8.6	35
48	Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. <i>Neuro-Oncology</i> , 2020, 22, 1831-1839.	1.2	34
49	Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching. <i>Journal of Molecular Biology</i> , 2016, 428, 4723-4735.	4.2	30
50	Integrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma. <i>EBioMedicine</i> , 2019, 46, 105-118.	6.1	30
51	KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 3719-3731.	0.9	30
52	Stereotactic Ablative Radiotherapy (SABR) for Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 845-854.	2.1	29
53	Comprehensive and Efficient HBB Mutation Analysis for Detection of \hat{I}^2 -Hemoglobinopathies in a Pan-Ethnic Population. <i>American Journal of Clinical Pathology</i> , 2010, 133, 700-707.	0.7	28
54	Structure-guided development of covalent TAK1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 838-846.	3.0	28

#	ARTICLE	IF	CITATIONS
55	KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry. <i>Structure</i> , 2017, 25, 1442-1448.e3.	3.3	27
56	Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1624-1641.	6.4	27
57	GADD45 \pm sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level. <i>Cell Death and Disease</i> , 2018, 9, 524.	6.3	26
58	Three-dimensional printer-aided casting of soft, custom silicone boluses (SCSBs) for head and neck radiation therapy. <i>Practical Radiation Oncology</i> , 2018, 8, e167-e174.	2.1	25
59	Significance testing as perverse probabilistic reasoning. <i>BMC Medicine</i> , 2011, 9, 20.	5.5	24
60	Structural basis of the atypical activation mechanism of KRASV14I. <i>Journal of Biological Chemistry</i> , 2019, 294, 13964-13972.	3.4	24
61	A pilot study using kernelled support tensor machine for distant failure prediction in lung SBRT. <i>Medical Image Analysis</i> , 2018, 50, 106-116.	11.6	22
62	Progress on Covalent Inhibition of KRASG12C. <i>Cancer Discovery</i> , 2016, 6, 233-234.	9.4	21
63	A Phase III Randomized Study of Image Guided Conventional (60 Gy/30 fx) Versus Accelerated, Hypofractionated (60 Gy/15 fx) Radiation for Poor Performance Status Stage II and III NSCLC Patientsâ€™ An Interim Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E451.	0.8	19
64	Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. <i>Cell Chemical Biology</i> , 2020, 27, 1229-1240.e4.	5.2	19
65	Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 57-68.	2.2	18
66	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1320-1328.	3.0	17
67	A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. <i>Journal of Biological Chemistry</i> , 2020, 295, 1565-1574.	3.4	17
68	Structure and Characterization of a Covalent Inhibitor of Src Kinase. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 81.	3.5	17
69	PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer. <i>Molecular Therapy</i> , 2022, 30, 621-631.	8.2	17
70	Rationale for <i>RAS</i> mutation-tailored therapies. <i>Future Oncology</i> , 2017, 13, 263-271.	2.4	16
71	Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6 <i>H</i> -benzo[<i>e</i>]pyrimido[5,4- <i>b</i>][1,4]diazepin-6-one Scaffold. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7817-7826.	6.4	16
72	Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 165.	8.6	15

#	ARTICLE	IF	CITATIONS
73	Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and Î±-Mangostin. PLoS ONE, 2016, 11, e0155217.	2.5	14
74	SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer. Lung Cancer, 2015, 89, 87-93.	2.0	13
75	Automated Text Message Reminders Improve Radiation Therapy Compliance. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1045-1052.	0.8	13
76	Mycotic aneurysm of the left main coronary artery producing acute coronary occlusion and purulent pericarditis. International Journal of Cardiology, 2007, 114, E81-E82.	1.7	12
77	Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiation Research, 2016, 185, 527-538.	1.5	11
78	Coordinating Tissue Regeneration Through Transforming Growth Factor-Î² Activated Kinase 1 Inactivation and Reactivation. Stem Cells, 2019, 37, 766-778.	3.2	10
79	Loss of wild type KRAS in KRAS lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors. Lung Cancer, 2021, 153, 73-80.	2.0	10
80	Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability. International Journal of Molecular Sciences, 2022, 23, 7095.	4.1	10
81	Small molecule inhibition of non-canonical (TAK1-mediated) BMP signaling results in reduced chondrogenic ossification and heterotopic ossification in a rat model of blast-associated combat-related lower limb trauma. Bone, 2020, 139, 115517.	2.9	9
82	Dynamic surveillance of tamoxifenâ€™resistance in ERâ€™positive breast cancer by CAIXâ€™targeted ultrasound imaging. Cancer Medicine, 2020, 9, 2414-2426.	2.8	8
83	The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51. PLoS Biology, 2021, 19, e3001281.	5.6	7
84	Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Cancer Research, 2021, 81, 4685-4695.	0.9	6
85	Structural dataset for the fast-exchanging KRAS G13D. Data in Brief, 2015, 5, 572-578.	1.0	5
86	Green Synthesis of Substituted Anilines and Quinazolines from Isatoic Anhydride-8-amide. Scientific Reports, 2019, 9, 14258.	3.3	5
87	Contact Tracing in Healthcare Settings During the COVID-19 Pandemic Using Bluetooth Low Energy and Artificial Intelligenceâ€™A Viewpoint. Frontiers in Artificial Intelligence, 2021, 4, 666599.	3.4	5
88	GTP hydrolysis is modulated by Arg34 in the RASopathyâ€™associated KRAS^{P34R}. Birth Defects Research, 2020, 112, 708-717.	1.5	4
89	Development of a realâ€™time indoor location system using bluetooth low energy technology and deep learning to facilitate clinical applications. Medical Physics, 2020, 47, 3277-3285.	3.0	4
90	Therapeutic Targeting the Allosteric Cysteine of RAS and Kinase Families. Journal of Molecular Biology, 2022, 434, 167626.	4.2	4

#	ARTICLE	IF	CITATIONS
91	Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as Prognostic Factors Following Stereotactic Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S621.	0.8	3
92	Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114433.	5.5	3
93	Structural Basis of Transcription. <i>Cell</i> , 2004, 119, 1055.	28.9	2
94	Predicting Distant Failure in Lung Stereotactic Body Radiation Therapy Using Multiobjective Radiomics Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S193-S194.	0.8	2
95	3D printer-assisted Soft Silicone Compensators for Electron Modulated Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E649.	0.8	2
96	Consolidative Radiotherapy for Limited Metastatic Non-Small Cell Lung Cancer: A Randomized Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1314.	0.8	2
97	ADAP1 promotes latent HIV-1 reactivation by selectively tuning KRAS-ERK-AP-1 T cell signaling-transcriptional axis. <i>Nature Communications</i> , 2022, 13, 1109.	12.8	2
98	Acid-Catalyzed Synthesis of Isatoic Anhydride-8-Secondary Amides Enables IASA Transformations for Medicinal Chemistry. <i>Journal of Organic Chemistry</i> , 2022, 87, 125-136.	3.2	2
99	Safety Analysis From a Prospective Registry Study of Stereotactic Body Radiation Therapy for Aggressive Management of Late-Stage Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E527.	0.8	1
100	GTP-Competitive Inhibitors of RAS Family Members. , 2017, , 155-174.		1
101	P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2261.	1.1	1
102	Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay. <i>STAR Protocols</i> , 2021, 2, 100587.	1.2	1
103	Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21571-e21571.	1.6	1
104	Impact of Superposition/convolution Dose Algorithm Inaccuracies in SBRT of Patients with Early Stage NSCLC: A Monte Carlo Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S792.	0.8	0
105	Should a Sentinel Node Biopsy be Performed in Patients with High Risk Breast Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, S256-S257.	0.8	0
106	Outcomes of Proton Beam Based SBRT in Medically Inoperable Stage I NSCLC. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S616-S617.	0.8	0
107	Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer?. <i>International Journal of Breast Cancer</i> , 2011, 2011, 1-5.	1.2	0
108	Developments in stereotactic ablative radiotherapy for the treatment of early-stage lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 129-139.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Development and Experience With an EMR-Based Radiation Oncology Toxicity Recording Instrument (ROTOX): Benchmarking and Quality Improvement. International Journal of Radiation Oncology Biology Physics, 2014, 90, S820.	0.8	0
110	(P084) Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer Tumors Greater Than 5 cm. International Journal of Radiation Oncology Biology Physics, 2017, 98, E38.	0.8	0
111	Use of Hypofractionated Radiation Therapy With Concurrent Chemotherapy in Inoperable Stage II/III Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E468.	0.8	0
112	Modern Non-operative Treatment Strategies for Patients With Stage II-III Non-small Cell Lung Cancer in the United States. International Journal of Radiation Oncology Biology Physics, 2017, 99, E468-E469.	0.8	0
113	A Support Tensor Machine Based Algorithm for Distant Failure Prediction in Lung SBRT. International Journal of Radiation Oncology Biology Physics, 2017, 99, E686-E687.	0.8	0
114	P3.08-004 Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC. Journal of Thoracic Oncology, 2017, 12, S2304.	1.1	0
115	Patterns of Failure after 5 Fraction Stereotactic Ablative Radiation Therapy in Early Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e696.	0.8	0
116	The to and fro of Rho. Structure, 2021, 29, 507-509.	3.3	0
117	Structural basis of RNA polymerase II substrate specificity and catalysis. FASEB Journal, 2007, 21, A656.	0.5	0
118	SU-FF-T-650: Dosimetric Benefit of a Combination of Respiratory-Gating, Image-Guidance and Intensity Modulated Radiation Therapy for Pancreatic Cancer Treatment. Medical Physics, 2009, 36, 2674-2674.	3.0	0
119	SU-E-T-545: Assessing the Impact of Proton Range Uncertainties on NSCLC Lung Patients Treated with Proton Beam-Based SBRT. Medical Physics, 2011, 38, 3614-3614.	3.0	0
120	Abstract PR07: Crystal structure of K-Ras G12C bound to an active site inhibitor. , 2014, , .		0
121	Abstract LB-031: Biochemical profiling of cancer-associated KRAS mutants: clues towards an understanding of differential clinical outcomes. , 2015, , .		0
122	Abstract 2852: Torin2 suppresses ionizing radiation induced DNA damage repair. , 2015, , .		0
123	Abstract A178: Structure guided development of irreversible inhibitors for TAK1. , 2015, , .		0
124	Safety and tolerability of concurrent Nab-P (Nab-P) and Carbo (Carbo) with thoracic radiotherapy (RT) followed by consolidative Nab-P and Carbo in patients with stage IIIA/B non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e20046-e20046.	1.6	0
125	Abstract 3354: Patterns of care for patients with non-operable T1-4 N+ M0 non-small cell lung cancer in the US and outcomes with radiation or chemotherapy monotherapies. , 2019, , .		0
126	Abstract IA03: KRAS Q61H preferentially signals through the MAPK pathway in non-small cell lung cancer. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
127	Abstract 4017: Biochemical and biophysical characterization of a covalent inhibitor of Src kinase. , 2020, , .		0
128	Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage. JTO Clinical and Research Reports, 2020, 1, 100094.	1.1	0
129	Abstract 3354: Patterns of care for patients with non-operable T1-4 N+ M0 non-small cell lung cancer in the US and outcomes with radiation or chemotherapy monotherapies. , 2019, , .		0